The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.
about
How animal models of leukaemias have already benefited patientsBCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.Embryo cryopreservation in a case of acute promyelocytic leukemia, incidentally diagnosed during ovarian stimulation for in-vitro fertilization.Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation.Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAcute promyelocytic leukemia: where does it stem from?Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.Acute myeloid leukemia developing in patients with autoimmune diseases.Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia.RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies.Management of elderly patients with acute promyelocytic leukemia: progress and problems.Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models.Successful management of pulmonary hemorrhage and aspergillosis in a patient with acute myeloid leukemia (AML-M3).Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology.Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.Acute myelogenous leukemia in adolescents and young adults.Oral and maxillofacial pathologies in young- and middle-aged adults.Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia
P2860
Q26997702-B481F84E-C491-470B-A826-7E80DDE0785CQ33335885-4EE6BEAE-5841-4344-B76B-E74C49D63199Q34500338-9CC20935-A68E-4364-9152-2B8490C18A74Q35150597-26207FE9-AA77-46A0-A035-1FD53DA1F59BQ35563628-60D6A962-1F62-4654-8B98-18698C54949EQ35635316-56C15F9D-9D7E-4739-9381-F479A7D605E3Q35651744-B657F5A5-AAAF-42D3-861A-8D7007E4D528Q35969759-2FAEDEEF-EF67-488D-AAAA-A90D7F4960F5Q36006358-DC5A4CED-7F3C-498C-B6EB-295C8101B623Q36623877-96C3E72A-A0B8-46EB-8312-E78ED760A4E9Q37103871-06F01D99-DE26-49E6-8F54-7124BA07FD4AQ37388701-27DCF64F-A0B3-432B-A54E-118E0C760557Q38108471-BA0BD1DD-1917-4E6F-AB4E-A045EB12DD33Q38228300-A667BD92-B775-441C-A84F-A469847C9984Q38240617-0EDB3C25-900E-4599-9BF1-BE3EA8DD4CC6Q38752325-F47DD9EE-8A52-4198-AC31-AD31616047E4Q41908857-8E895DB0-0BA3-48B5-ADE4-7904E14BCB7BQ43125640-323DFD9C-1442-482B-B742-55CB052C7716Q43163882-E496895F-E48A-4CC1-BAA5-A366A8DD6EB6Q46104696-23B7E963-D92A-4050-BD26-DBBA55DB7828Q46713722-C055FAB7-1E34-4E6F-9AD3-0F461B659A0DQ52318200-F064CAE3-9F36-4900-9BDE-0CEB2B7A98E8Q53646394-BAF6E85C-0C8C-4E53-B29B-892D55E394DBQ55337080-F0A7FA56-618A-4711-89C2-A13925CCFC11Q57217375-0D990921-EAEA-4D5E-B45C-38CFAF582EEA
P2860
The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The incidence of acute promyel ...... ly one rate limiting mutation.
@ast
The incidence of acute promyel ...... ly one rate limiting mutation.
@en
The incidence of acute promyel ...... ly one rate limiting mutation.
@nl
type
label
The incidence of acute promyel ...... ly one rate limiting mutation.
@ast
The incidence of acute promyel ...... ly one rate limiting mutation.
@en
The incidence of acute promyel ...... ly one rate limiting mutation.
@nl
prefLabel
The incidence of acute promyel ...... ly one rate limiting mutation.
@ast
The incidence of acute promyel ...... ly one rate limiting mutation.
@en
The incidence of acute promyel ...... ly one rate limiting mutation.
@nl
P2093
P356
P1433
P1476
The incidence of acute promyel ...... ly one rate limiting mutation.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2401722
P577
2000-04-01T00:00:00Z
P5875
P6179
1026856091